Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy.
Biomarker
HCC
Interventional oncology
microRNA
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
28 Jul 2023
28 Jul 2023
Historique:
received:
18
02
2023
accepted:
05
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Prognostic biomarkers identifying patients with early tumor progression after local ablative therapy remain an unmet clinical need. The aim of this study was to investigate circulating miR-21 and miR-210 levels as prognostic biomarkers of HCC treated by CT-guided high-dose rate brachytherapy (HDR-BT). 24 consecutive HCC patients (BCLC A and B) treated with CT-guided HDR-BT (1 × 15 Gy) were included in this prospective IRB-approved study. RT-PCR was performed to quantify miR-21 and miR-210 levels in blood samples acquired prior to and 2 d after HDR-BT. Follow-up imaging (contrast-enhanced liver MRI and whole-body CT) was performed in 3 months follow-up intervals. Therapy response was assessed with patients classified as either responders or non-responders (12 each). Responders were defined as having no local or diffuse systemic progression within 6 months and no diffuse systemic progression exceeding 3 nodules/nodule diameter > 3 cm from 6 months to 2 years. Non-responders had recurrence within 6 months and/or tumor progression with > 3 nodules or individual lesion diameter > 3 cm or extrahepatic disease within two years, respectively. Biostatistics included parametric and non-parametric testing (Mann-Whitney-U-test), as well as Kaplan-Meier curve construction. The responder group demonstrated significantly decreasing miR-21 values 2 d post therapy compared to non-responders (median miR-21 2 Increasing circulating miR-21 levels are associated with poor response and shorter time to systemic progression in HDR-BT-treated HCC. This proof-of-concept study provides a basis for further investigation of miR-21 as a prognostic biomarker and potential stratifier in future clinical trials of interventional oncology therapies. In this monocentric clinical study, we analyzed prospectively acquired data of 24 patients from the "ESTIMATE" patient cohort (Studiennummer: DRKS00010587, Deutsches Register Klinischer Studien). Ethical approval was provided by the ethics committee "Ethikkommission bei der LMU München" (reference number "17-346") on June 20, 2017 and August 26, 2020.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Prognostic biomarkers identifying patients with early tumor progression after local ablative therapy remain an unmet clinical need. The aim of this study was to investigate circulating miR-21 and miR-210 levels as prognostic biomarkers of HCC treated by CT-guided high-dose rate brachytherapy (HDR-BT).
MATERIALS AND METHODS
METHODS
24 consecutive HCC patients (BCLC A and B) treated with CT-guided HDR-BT (1 × 15 Gy) were included in this prospective IRB-approved study. RT-PCR was performed to quantify miR-21 and miR-210 levels in blood samples acquired prior to and 2 d after HDR-BT. Follow-up imaging (contrast-enhanced liver MRI and whole-body CT) was performed in 3 months follow-up intervals. Therapy response was assessed with patients classified as either responders or non-responders (12 each). Responders were defined as having no local or diffuse systemic progression within 6 months and no diffuse systemic progression exceeding 3 nodules/nodule diameter > 3 cm from 6 months to 2 years. Non-responders had recurrence within 6 months and/or tumor progression with > 3 nodules or individual lesion diameter > 3 cm or extrahepatic disease within two years, respectively. Biostatistics included parametric and non-parametric testing (Mann-Whitney-U-test), as well as Kaplan-Meier curve construction.
RESULTS
RESULTS
The responder group demonstrated significantly decreasing miR-21 values 2 d post therapy compared to non-responders (median miR-21 2
CONCLUSION
CONCLUSIONS
Increasing circulating miR-21 levels are associated with poor response and shorter time to systemic progression in HDR-BT-treated HCC. This proof-of-concept study provides a basis for further investigation of miR-21 as a prognostic biomarker and potential stratifier in future clinical trials of interventional oncology therapies.
TRIAL REGISTRATION
BACKGROUND
In this monocentric clinical study, we analyzed prospectively acquired data of 24 patients from the "ESTIMATE" patient cohort (Studiennummer: DRKS00010587, Deutsches Register Klinischer Studien). Ethical approval was provided by the ethics committee "Ethikkommission bei der LMU München" (reference number "17-346") on June 20, 2017 and August 26, 2020.
Identifiants
pubmed: 37507808
doi: 10.1186/s13014-023-02316-2
pii: 10.1186/s13014-023-02316-2
pmc: PMC10375621
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
MIRN21 microRNA, human
0
MIRN210 microRNA, human
0
Banques de données
DRKS
['DRKS00010587']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB841
Organisme : ERC advance - GA
ID : No. 786575 - RxmiRcanceR
Organisme : Israeli Science Foundation
ID : 904/2020
Informations de copyright
© 2023. The Author(s).
Références
Biomark Med. 2018 Oct;12(10):1105-1114
pubmed: 30191729
J Clin Med. 2016 Mar 16;5(3):
pubmed: 26999230
J Cancer Res Clin Oncol. 2022 Oct;148(10):2815-2826
pubmed: 35596772
Front Med (Lausanne). 2020 Jan 31;7:7
pubmed: 32083086
Hepatology. 2011 Dec;54(6):2064-75
pubmed: 22144109
Asian Pac J Cancer Prev. 2019 May 25;20(5):1587-1593
pubmed: 31128066
Nat Rev Mol Cell Biol. 2019 Jan;20(1):21-37
pubmed: 30108335
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):172-9
pubmed: 20056348
Gut. 2016 Sep;65(9):1535-45
pubmed: 27196584
Biomed Res Int. 2020 Dec 21;2020:8848158
pubmed: 33415165
Oncotarget. 2017 Jul 4;8(27):44050-44058
pubmed: 28477010
Cancer Cell Int. 2020 Aug 10;20:384
pubmed: 32788885
Strahlenther Onkol. 2015 May;191(5):405-12
pubmed: 25404063
Int J Clin Exp Pathol. 2015 Jun 01;8(6):7234-8
pubmed: 26261620
J Vasc Interv Radiol. 2021 Mar;32(3):403-411
pubmed: 33495063
Gastroenterology. 2007 Aug;133(2):647-58
pubmed: 17681183
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Oncol Rep. 2016 Nov;36(5):2553-2562
pubmed: 27666683
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
Int J Clin Exp Pathol. 2018 Aug 01;11(8):4169-4178
pubmed: 31949811
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Ann Oncol. 2019 May 1;30(5):871-873
pubmed: 30715202
In Vivo. 2022 Sep-Oct;36(5):2265-2274
pubmed: 36099091
Evid Based Complement Alternat Med. 2020 Jul 17;2020:2892917
pubmed: 32724322
World J Hepatol. 2020 Nov 27;12(11):1031-1045
pubmed: 33312427
J Exp Clin Cancer Res. 2018 Dec 27;37(1):324
pubmed: 30591064